Dyne Therapeutics (NASDAQ:DYN) executives outlined a slate of 2026 operational and regulatory milestones during a discussion with Stifel, emphasizing plans to transition toward a commercial-stage organization while advancing multiple neuromuscular disease programs. Chief Financial Officer Erick Lucera, joined by Chief Scientific Officer Ranjan Batra, said the company views 2026 as a potential “breakout year,” following […]